12 Results

People

  1. Scher
    Scher
  2. Morris
    Morris
  3. Rathkopf
    Rathkopf
  4. Danila
    Danila
  5. Fleisher
    Fleisher
  6. Heller
    Heller
  7. McBride
    McBride
  8. Slovin
    Slovin
  9. Autio
    Autio
  10. Bambury
    Bambury

Groups

  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Genitourinary Oncology Service (10)
  4. Biostatistics Service (4)
  5. Epidemiology and Biostatistics (4)
  6. Survivorship Research (3)
  7. GDMT, Radiation Oncology (2)
  8. Gynecology Disease Management Team (2)
  9. Hematologic Malignancies, Division of (2)
  10. Molecular Imaging and Therapy Service (2)
  1. "androgen receptor antagonists"
Formats
  1. Journal Article (12)
Groups
  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Genitourinary Oncology Service (10)
  4. Biostatistics Service (4)
  5. Epidemiology and Biostatistics (4)
  6. Survivorship Research (3)

More Groups

People
  1. Howard Scher (6)
  2. Dana Rathkopf (5)
  3. Michael Morris (3)
  4. Daniel Danila (2)
  5. Glenn Heller (2)
  6. Marisa Kollmeier (2)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (1)
  4. 2019 (1)
  5. 2016 (2)
  6. 2014 (1)

More Years

Publications
  1. Clinical Cancer Research (3)
  2. European Urology (1)
  3. JAMA Oncology (1)
  4. Journal of Clinical Oncology (1)
  5. Journal of Urology (1)
  6. Lancet Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. Elsevier Science, Inc. (3)
  3. American Medical Association (1)
  4. American Society of Clinical Oncology (1)
  5. Elsevier Inc. (1)
  6. Future Medicine (1)

More Publishers

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)
    Journal Article

    Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Miller, B. C.; Hillman, D. W.; Heller, G.; Druley, T.; Armstrong, A. J.; Morris, M. J.; Milowsky, M. I.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
    Journal Article

    Dorff, T.; Horvath, L. G.; Autio, K.; Bernard-Tessier, A.; Rettig, M. B.; Machiels, J. P.; Bilen, M. A.; Lolkema, M. P.; Adra, N.; Rottey, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer
    Journal Article

    Sperger, J. M.; Helzer, K. T.; Stahlfeld, C. N.; Jiang, D.; Singh, A.; Kaufmann, K. R.; Niles, D. J.; Heninger, E.; Rydzewski, N. R.; Wang, L.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open-label, randomised, phase 3 trial
    Journal Article

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    Journal Article

    Pan, A.; Reingold, R. E.; Zhao, J. L.; Moy, A.; Kraehenbuehl, L.; Dranitsaris, G.; McBride, S. M.; Scher, H. I.; Kollmeier, M. A.; Xiao, H.; more...
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy
    Journal Article

    Patel, M. A.; Kollmeier, M.; McBride, S.; Gorovets, D.; Varghese, M.; Chan, L.; Knezevic, A.; Zhang, Z.; Zelefsky, M. J.
    Radiotherapy and Oncology (2019)

    Fulltext@MSK | Save
  • Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Lu, D.; Schreiber, N. A.; Louw, J.; Graf, R. P.; Vargas, H. A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; more...
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • Prior endocrine therapy impact on abiraterone acetate clinical efficacy in metastatic castration-resistant prostate cancer: Post-hoc analysis of randomised phase 3 studies
    Journal Article

    Bellmunt, J.; Kheoh, T.; Yu, M. K.; Smith, M. R.; Small, E. J.; Mulders, P. F. A.; Fizazi, K.; Rathkopf, D. E.; Saad, F.; Scher, H. I.; more...
    European Urology (2016)

    Fulltext@MSK | Save
  • Enzalutamide in metastatic prostate cancer before chemotherapy
    Journal Article

    Beer, T. M.; Armstrong, A. J.; Rathkopf, D. E.; Loriot, Y.; Sternberg, C. N.; Higano, C. S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S.; more...
    New England Journal of Medicine (2014)

    Fulltext@MSK | Save
  • Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Morris, M. J.; Fox, J. J.; Danila, D. C.; Slovin, S. F.; Hager, J. H.; Rix, P. J.; Chow-Maneval, E.; Chen, I.; Gonen, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save